Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Tongji XieZihua ZouChengcheng LiuYi-Xiang ZhuZiyi XuLe WangJun-Ling LiPu-Yuan XingPublished in: Evidence-based complementary and alternative medicine : eCAM (2021)
In this NMA, osimertinib and SoC combined with chemotherapy would be the optimal first-line treatment options for advanced NSCLC patients harboring EGFR 19 deletion mutation and 21 Leu858Arg mutation, respectively. This finding is likely to be adopted in clinical practice and provide guidance for future clinical study design. Systematic review registration: INPLASY2020100059.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- small cell lung cancer
- systematic review
- tyrosine kinase
- clinical practice
- end stage renal disease
- newly diagnosed
- ejection fraction
- stem cells
- meta analyses
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- squamous cell carcinoma
- mesenchymal stem cells
- bone marrow
- patient reported